Investor Presentation - First Nine Months of 2016
Investor presentation
First nine months of 2016
Slide 45
US premix insulin
Segment volume
NovoLogⓇ market share
Novo Nordisk's modern insulins maintain market share in
expanding US insulin market
US fast-acting insulin
Segment volume
US long-acting insulin
Segment volume
NovoLogⓇ Mix 70/30 market share
LevemirⓇ market share
tMU
tMU
tMU
CAGR volume¹: 3.0%
80
100%
80
MI penetration: 83.0%
CAGR volume¹: (6.1%),
MI penetration: 53.3%
CAGR volume¹: 3.8%
100%
80
100%
MI penetration: 83.7%
70
70
70
80%
80%
80%
60
60
60
50
+60%
50
60%
50
60%
40
40
40
40%
40%
40%
30
30
30
20
20
20
20%
20%
20%
10
10
10
0
0%
0%
0
0%
Aug
2011
Aug
0
2016
Aug
2011
Aug
Aug
Aug
2016
2011
2016
1 CAGR for 5-year period
Note: US trend data reflect changes to IMS data collection coverage and methodology as of January 2012. Modern insulin (MI) penetration is of total segment, ie including human insulin
Source: IMS Monthly MAT August, 2016 volume figures
changing
diabetes®
novo nordiskView entire presentation